Sponsored by:

Radiopharmaceutical Therapy Tracker

Mar 30, 2026
Rt Tracker

Fueled by theranostics, new radiopharmaceutical therapies to treat cancer are advancing at a blistering pace. To help keep up with the dynamic landscape, AuntMinnie has launched the Radiopharmaceutical Therapy Tracker. Readers with new entries or updates are welcome to reach us at [email protected].

Last Updated: May 22, 2026 ↓
Latest News: May 22, 2026 ▾
Company Drug (Isotope) / Imaging Agent Indication(s) / Target Phase

 

Latest in Nuclear Medicine
Martin Pomper, MD, PhD
SNMMI awards Martin Pomper 2026 Benedict Cassen Prize
June 1, 2026
Asco Thumb
ASCO: Lu-177 edotreotide yields sustained quality-of-life gains
May 31, 2026
Advancing molecular imaging together
Sponsored
Advancing molecular imaging together
May 24, 2026
Business Handshake 400 (1)
Mevion to install first proton therapy system in Vietnam
May 26, 2026
Related Stories
Cancertarget
Nuclear Medicine
Archeus doses first patient in phase I RPT trial
Business Deal Handshake
Molecular Imaging
Telix and Regeneron enter $2.1B partnership
Pet Brain Scan Adobe Michael dim5r Awl G7
Neuroradiology
FDA accepts Telix NDA for glioma PET agent Pixclara
Advancing molecular imaging together
Sponsor Content
Advancing molecular imaging together
More in Nuclear Medicine
SNMMI awards Martin Pomper 2026 Benedict Cassen Prize
By AuntMinnie.com staff writers
The SNMMI has awarded Martin Pomper, MD, PhD, the Benedict Cassen Prize for his contributions toward nuclear medicine research.
June 1, 2026
Martin Pomper, MD, PhD
ASCO: Lu-177 edotreotide yields sustained quality-of-life gains
By Erik L. Ridley
A poster presentation at ASCO 2026 highlighted quantifiable benefits for patients receiving the radiopharmaceutical treatment for GEP-NETs.
May 31, 2026
Asco Thumb
Archeus doses first patient in phase I RPT trial
By AuntMinnie.com staff writers
In preclinical work, Y-90 ARC-706 demonstrated tumor-selective uptake across multiple ICI-treated cancers.
May 27, 2026
Cancertarget
Mevion to install first proton therapy system in Vietnam
By AuntMinnie.com staff writers
Mevion Medical Systems has signed an agreement to install what the firm says will be the first proton therapy system in Vietnam.
May 26, 2026
Business Handshake 400 (1)
Radnostix reports 27% revenue decline in Q1
By AuntMinnie.com staff writers
Radnostix reported a 27% decrease in the first quarter of 2026 compared to the previous year's first quarter.
May 21, 2026
Research Money 400
Niowave breaks ground on $75M Mich. Ac-225 production facility
By AuntMinnie.com staff writers
Niowave has broken ground on its Ac-225 production facility in Lansing, MI, with construction expected to be finished by 2028.
May 21, 2026
Construction Pharmaceutical Manufacturing 400
NRC to ease burden on radiopharmaceutical licensees
By AuntMinnie.com staff writers
The rule would eliminates decommissioning financial assurance (DFA) for all radionuclides with half-lives of 120 days or less.
May 19, 2026
Isotopes1
Plus Therapeutics inks AI deal with Ephemeral Technologies
By AuntMinnie.com staff writers
Plus Therapeutics is a clinical-stage pharmaceutical company developing radiopharmaceutical therapies for CNS cancers.
May 19, 2026
Ai Handshake
SNMMI highlights new radiopharmaceutical therapy
By AuntMinnie.com staff writers
Mice bearing PDAC xenografts received lutetium-177 (Lu-177) AKIR001, a radiopharmaceutical that targets CD44v6.
May 13, 2026
Biodistribution of Lu-177 AKIR001. (A) Mice (N = 12) bearing BxPC3 tumors were injected with Lu-177 AKIR001 and dissected at 24 (N = 4), 96 (N = 4), and 168 hours (N = 4) postinjection. Error bars represent SD. (B) Representative SPECT/CT images at 96 hours postinjection. GI = gastrointestinal.
Eden Radioisotopes files NRC permit for isotope production complex
By AuntMinnie.com staff writers
The company said the facility is designed to produce up to 50% of global demand for molybdenum-99 (Mo-99).
May 6, 2026
Isotopes
C-Ray Therapeutics wins FDA active status for Cu-64 drug master file
By AuntMinnie.com staff writers
C-Ray Therapeutics has received active status from the FDA for its Type II Drug Master File for Cu-64 chloride for radiolabeling.
April 28, 2026
Fda Button 400
TAG1, NRG Pallas to advance Pb-212 supply for cancer therapies
By AuntMinnie.com staff writers
TAG1 and NRG Pallas aim to develop access to lead-212 (Pb-212) for cancer drug development across Europe.
April 22, 2026
A Rk Nx1 Fop15 Je H Jffj8rq D13
Page 1 of 442
Next Page